Taking into account the high prevalence of KMT2A rearrangements in pediatric AML-pCT, menin inhibitors, blocking the oncogenic function of the KMT2A complex, might be also studied in that group. The gene discussed is KMT2A; the disease is acute myeloid leukemia.